Preview

Russian Journal of Cardiology

Advanced search

Factors associated with the risk of progression and decompensation of heart failure in patients with an implantable cardioverter-defibrillator

https://doi.org/10.15829/1560-4071-2024-5619

EDN: YUEMYV

Abstract

Aim. To analyze clinical and anamnestic factors associated with the risk of acute decompensated heart failure (ADHF) in patients with an implanted cardioverter-defibrillator (ICD) with the development of a prognostic model based on the Kuzbass registry of patients with ICD.

Material and methods. Prospective follow-up of 260 patients with reduced left ventricular ejection fraction (age 59 (53; 66) years, 214 (82,3%) men) from the Kuzbass registry of patients with ICD. Of them, 156 (60%) patients had ischemic cardiomyopathy, while the rest had non-ischemic cardiomyopathy. The mean follow-up period was 4,2±2,3 years after ICD implantation. The following basic information about patients were assessed: demographic data, social status, history of the underlying disease, concomitant diseases, vital signs, standard clinical and paraclinical parameters, drug therapy. During the follow-up period, all cases of ADHF and death were analyzed.

Results. A total of 54 (20,8%) patients died, of which 48 (88,9%) died due to ADHF. During the follow-up period, 34 patients were hospitalized for ADHF, of which 13 (38,2%) died. Thirty-five (13,5%) patients died in the prehospital stage due to ADHF that developed against the background of the underlying disease (10 (27%) had dilated cardiomyopathy, 1 (2,8%) — rheumatic mitral valve disease, 24 (68,6%) — ischemic cardiomyopathy). Thus, a total of 69 cases of ADHF were registered, which accounted for 26,5% of the total group. Mortality in general group from ADHF was 18,5%. According to the Kaplan-Meier curve, most deaths occurred during the first 1,5 years of follow-up.

The regression model for predicting the ADHF risk included left atrium size (p=0,05), male sex (p=0,001), NYHA class (p=0,0001), left ventricular ejection fraction <40% (p=0,0001), no intake of renin-angiotensin-aldosterone system inhibitors (p=0,007) and amiodarone (p=0,028). The area under the ROC curve (AUC), sensitivity and specificity of the created model was 0,8, 69,2% and 80%, respectively.

Conclusion. A set of routine clinical and anamnestic factors has been identified that makes it possible to predict the risk of ADHF in patients with ICDs, which must be taken into account before making a decision to implant the device. Particular attention should be paid to mandatory therapy for heart failure, as the main modifiable risk factor for ADHF.

About the Authors

N. B. Lebedeva
Research Institute of Complex Issues of Cardiovascular Diseases
Russian Federation

Kemerovo


Competing Interests:

none



I. V. Talibullin
Research Institute of Complex Issues of Cardiovascular Diseases
Russian Federation

Kemerovo


Competing Interests:

none



P. G. Parfenov
Research Institute of Complex Issues of Cardiovascular Diseases
Russian Federation

Kemerovo


Competing Interests:

none



A. P. Egle
Research Institute of Complex Issues of Cardiovascular Diseases
Russian Federation

Kemerovo


Competing Interests:

none



O. L. Barbarash
Research Institute of Complex Issues of Cardiovascular Diseases
Russian Federation

Kemerovo


Competing Interests:

none



References

1. Boriani G, De Ponti R, Guerra F, et al. Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. Eur J PrevCardiol. 2021;28(1):110-23. doi:10.1093/eurjpc/zwaa015.

2. Bogachevskaja, SA, Bogachevskij AN. Development of surgical and interventional arrhythmology in Russia over 10 years. Features of the functioning of the service in the Far East region. Social'nye aspekty zdorov'ja naselenija. 2017;1(53):2. (In Russ.)

3. Vinogradova NG, Polyakov DS, Fomin IV. Analysis of mortality in patients with heart failure after decompensation during long-term follow-up in specialized medical care and in real clinical practice. Kardiologiia. 2020;60(4):91-100. (In Russ.) doi:10.18087/cardio.2020.4.n1014.

4. Rizzello V. Selection of patients eligible for implantable cardioverter defibrillator: beyond left ventricular ejection fraction. European Heart Journal Supplements. 2022;24(1):1139-42. doi:10.1093/eurheartjsupp/suac087.

5. Tereshchenko SN, Galyavich AS, Uskach TM, et al. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.

6. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed in 20 years of observation? The results of the study EPOCHA-CHF. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.

7. Rychkov AYu, Kuznetsov VA, Dyuryagina EL, et al. Frequency of appropriate activations of implanted cardioverters-defibrillators in patients with chronic heart failure. Journal of Arrhythmology. 2015;(81):10-4. (In Russ.)

8. Ilov NN, Palnikova OV, Nechepurenko AA, et al. Patients with high SCD risk: a life after cardio­verter-defibrillators implantation (single-center observational trial). Clin Experiment Surg. Petrovsky J. 2018;6(3):98-106. (In Russ.) doi:10.24411/2308-1198-2018-13011.

9. Kamaliev MA, Al'muhanova AB, Bapaeva M, et al. Medical efficiency after implantation of the cardioverter-defibrillator. Vestnik Kazahskogo Nacional'nogo medicinskogo universiteta. 2018;3:283-4. (In Russ.)

10. Zabel M, Willems R, Lubinski A, et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41:3437-47. doi:10.1093/eurheartj/ehaa226.

11. Zacà V. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. J CardiovascMed (Hagerstown). 2018;19(10):597-605. doi:10.2459/JCM.0000000000000708.

12. Al-Khatib SM, Mi X, Wilkoff BL, et al. Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice? Circ. Arrhythm. Electrophysiol. 2013;6(1):108-16. doi:10.1161/CIRCEP.112.974337.

13. Matsuzoe H, Tanaka H, Matsumoto K, et al. Left ventricular dyssynergy and dispersion as determinant factors of fatal ventricular arrhythmias in patients with mildly reduced ejection fraction. Eur Heart J Cardiovasc Imaging. 2016;17(3):334-42. doi:10.1093/ehjci/jev172.

14. Frolov AV, Vaikhanskaya TG, Melnikova ОР, et al. Risk stratification personalised model for prediction of life-threatening ventricular tachyarrhythmias in patients with chronic heart failure. Kardiologia Polska. 2017;75(7):682-8. doi:10.5603/KP.a2017.0060.

15. Naksuk N, Akkaya M, Adabag S. Application of the Multicenter Automatic Defibrillator Implantation Trial II risk score in a nontrial setting. Am J Cardiol. 2013;112(4):530-2. doi:10.1016/j.amjcard.2013.04.019.

16. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of sur­vival in heart failure. Circulation. 2006;113(11):1424-33. doi:10.1161/CIRCULATIONAHA.105.584102.

17. Younis A, Goldberger JJ, Kutyifa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J. 2021;42(17):1676-84. doi:10.1093/eurheartj/ehaa1057.

18. Al‐Majed NS, McAlister FA. Meta‐analysis: cardiac resynchronization therapy for pati­ents with less symptomatic heart failure. Ann Intern Med. 2011;154(6):401‐12. doi:10.7326/0003­4819­154­6­201103150­00313.

19. Greene SJ, Butler J, Fonarow GC. Simultaneous or Rapid Sequence Initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed. JAMA Cardiol. 2021;6(7):743-4. doi:10.1001/jamacardio.2021.0496.

20. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of compre­hensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-8. doi:10.1016/S0140-6736(20)30748-0.

21. Van der Bijl P, Bax JJ. Imaging for risk stratification of sudden cardiac death. Herz­schrittmacherther Elektrophysiol. 2022;33(3):261-7. doi:10.1007/s00399-022-00884-6.

22. Kammoun I, Bennour E, Laroussi L, et al. Risk stratification for sudden cardiac death in pati­ents with heart failure: Emerging role of imaging parameters. Herz. 2021;46(6):550-7. doi:10.1007/s00059-021-05032-3.


Supplementary files

  • In patients with reduced left ventricular ejection fraction and an implantable cardioverter-­defi­brillator (ICD), the prognosis is largely determined by the risk of acute decompensated heart failure.
  • A personalized approach is needed to determine the need for ICD implantation.
  • Based on routine clinical and anamnestic factors determined before ICD implantation, a novel predictive model for acute decompensated heart failure, convenient for practical use, was created.

Review

For citations:


Lebedeva N.B., Talibullin I.V., Parfenov P.G., Egle A.P., Barbarash O.L. Factors associated with the risk of progression and decompensation of heart failure in patients with an implantable cardioverter-defibrillator. Russian Journal of Cardiology. 2024;29(3):5619. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5619. EDN: YUEMYV

Views: 431


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)